{"id":2812,"date":"2026-09-01T08:00:00","date_gmt":"2026-09-01T12:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=2812"},"modified":"2026-09-01T22:18:33","modified_gmt":"2026-09-02T02:18:33","slug":"envudeucitinib-misses-overall-sle-endpoints-biomarker-subgroup-separates","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=2812","title":{"rendered":"Envudeucitinib Misses Overall SLE Endpoints; Biomarker Subgroup Separates"},"content":{"rendered":"

Company:<\/strong> Alumis · Drug:<\/strong> Envudeucitinib · Trial:<\/strong> LUMUS (Phase 2b) · Indication:<\/strong> Systemic Lupus Erythematosus · Date:<\/strong> September 1, 2026<\/p>\n

\"Envudeucitinib<\/p>\n

Summary<\/h4>\n

Alumis reported that the 408-patient Phase 2b LUMUS trial of envudeucitinib in systemic lupus erythematosus did not meet its Week-48 BICLA primary endpoint or key secondary endpoints in the overall population. BICLA response was 35.7% with placebo and 40.0% to 42.2% across active doses, with all primary comparisons nonsignificant. A prespecified interferon-gene-signature-high subgroup showed dose-related separation, while the IFNGS-low subgroup moved in the opposite direction. Alumis plans FDA and EMA discussions before deciding Phase 3 design; a Phase 3 start is not established.<\/p>\n

What Happened<\/h4>\n

LUMUS randomized adults with moderate-to-severe autoantibody-positive SLE to placebo, envudeucitinib 20 mg once daily, 20 mg twice daily or 40 mg twice daily. In the overall population, BICLA response rates were 35.7%, 40.0%, 42.2% and 41.0% respectively, with p values versus placebo ranging from 0.3455 to 0.5018. Only about 60% of participants were IFNGS-high, below company expectations. In that prespecified subgroup, 40 mg twice daily produced a 52.6% BICLA response versus 28.6% for placebo, an adjusted 24.0-point difference. In IFNGS-low patients, the same dose produced 24.4% versus 47.5%, an adjusted negative 23.0-point difference. Alumis reported no new safety signal and lower aggregate adverse-event rates on active treatment, but detailed exposure-adjusted safety data remain limited.<\/p>\n

Deep Analysis<\/h4>\n

The IFNGS-high analysis was prespecified, mechanistically aligned with type-I-interferon signaling and internally coherent across BICLA, SRI-4, skin, joint and low-disease-activity measures, and dose-dependent pharmacodynamic suppression supports target engagement. Subgroup sizes were roughly 60 patients per arm, however, the overall trial failed, multiple subgroup endpoints were examined and no prospectively powered biomarker-enriched trial has replicated the effect. An unexpectedly large IFNGS-low fraction and high placebo response could dilute a real effect in responsive biology, but the inverse result in IFNGS-low patients may also reflect random imbalance or a genuinely limited therapeutic window; the data do not establish that enrichment alone will reproduce efficacy.<\/p>\n

Company and Product Background<\/h4>\n

Alumis develops oral precision immunology medicines. Envudeucitinib is an investigational allosteric TYK2 inhibitor designed for sustained blockade of signaling downstream of type-I interferons and IL-12\/IL-23-family cytokines while limiting broader JAK inhibition. It is also in late-stage development for plaque psoriasis, where Alumis continues to target a fourth-quarter 2026 NDA filing. SLE is a heterogeneous autoimmune disease affecting skin, joints, kidneys, blood and other organs; type-I-interferon pathway activation is common but not universal, and BICLA is a composite response requiring improvement in active organ domains without worsening elsewhere.<\/p>\n

Signal Extraction<\/h4>\n\n\n\n\n\n\n\n
Factor<\/th>\nAssessment<\/th>\n<\/tr>\n
Trial<\/td>\nLUMUS, 408 patients, Phase 2b, randomized placebo-controlled<\/td>\n<\/tr>\n
Overall Result<\/td>\nBICLA primary and key secondary endpoints not met; p values 0.3455-0.5018<\/td>\n<\/tr>\n
IFNGS-High Subgroup<\/td>\n52.6% vs. 28.6% BICLA (40mg BID); adjusted +24.0-point difference<\/td>\n<\/tr>\n
IFNGS-Low Subgroup<\/td>\n24.4% vs. 47.5% BICLA (40mg BID); adjusted -23.0-point difference<\/td>\n<\/tr>\n
Next Steps<\/td>\nFDA\/EMA discussions planned; Phase 3 design and start not established<\/td>\n<\/tr>\n<\/table>\n

Reading the Signal<\/h4>\n

Bull case:<\/strong> A prespecified, mechanistically grounded IFNGS-high subgroup showed a coherent 24-point BICLA separation across multiple endpoints and dose-dependent pharmacodynamic suppression, offering a credible biomarker-enrichment path forward.<\/p>\n

Bear case:<\/strong> The overall Phase 2b trial failed on its primary endpoint, the IFNGS-low subgroup moved in the opposite direction, and no prospectively powered enriched trial has yet replicated the effect, so the rescue hypothesis remains unconfirmed.<\/p>\n

InSilens Take<\/h4>\n

The overall Phase 2b failure is the controlling fact; the IFNGS-high result is a credible but unconfirmed rescue hypothesis. It is stronger than an unplanned post hoc slice because the subgroup was prespecified, mechanistically grounded and directionally consistent across endpoints, but weaker than a positive trial because the same program showed little overall effect and an inverse pattern in IFNGS-low patients. The defensible next step is regulator-vetted biomarker enrichment with prospective replication, not a claim that efficacy is established in SLE.<\/p>\n

Signal Assessment<\/h4>\n

Importance:<\/strong> 4\/5 · Direction:<\/strong> Mixed · Confidence:<\/strong> High on facts, Moderate-low on interpretation<\/p>\n","protected":false},"excerpt":{"rendered":"

Alumis reported that the 408-patient Phase 2b LUMUS trial of envudeucitinib in systemic lupus erythematosus did not meet its Week-48 BICLA primary endpoint or key secondary endpoints in the overall population. BICLA response was…<\/p>\n","protected":false},"author":1,"featured_media":2826,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,3],"tags":[492,493,494,495],"class_list":["post-2812","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-clinical","category-therapeutic-indication","tag-alumis","tag-envudeucitinib","tag-systemic-lupus-erythematosus","tag-tyk2-inhibitor"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2812","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2812"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2812\/revisions"}],"predecessor-version":[{"id":2838,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2812\/revisions\/2838"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/2826"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2812"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2812"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2812"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}